Histone deacetylase inhibitors as a potential new treatment for psoriatic disease and other inflammatory conditions

References

• Christophers E. Psoriasis − epidemiology and clinical spectrum: psoriasis − epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320.
   PubMed Web of Science ®Google Scholar
• Lomholt G. Prevalence of skin diseases in a population; a census study from the Faroe islands. Dan Med Bull. 1964;11:1–7.
   PubMedGoogle Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450–456.
   PubMed Web of Science ®Google Scholar
• Ortonne J, Chimenti S, Luger T, et al. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(12):1435–1444.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Ko HC, Jwa SW, Song M, et al. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol. 2010;37(10):894–899.
   PubMed Web of Science ®Google Scholar
• Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol. 1996;132(6):717–718.
   PubMedGoogle Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
   PubMed Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799.
   PubMed Web of Science ®Google Scholar
• Papp K, Gulliver W, Lynde C, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210–219.
   PubMed Web of Science ®Google Scholar
• Feldman SR. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl_2):ii65–8.
   PubMedGoogle Scholar
• Bhosle MJ, Kulkarni A, Feldman SR, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.
   PubMed Web of Science ®Google Scholar
• Fortune DG, Richards HL, Griffiths CEM. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23(4):681–694.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24–28.
   PubMed Web of Science ®Google Scholar
• de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144 Suppl 58(Suppl 58):33–36.
   PubMedGoogle Scholar
• Feldman SR, Fleischer AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37(4):564–569.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236–244.
   PubMed Web of Science ®Google Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. Longo DL, editor. N Engl J Med. 2017;376(10):957–970.
   PubMed Web of Science ®Google Scholar
• Eder L, Polachek A, Rosen CF, et al. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol. 2017;69(3):622–629.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–2673.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78.
   PubMedGoogle Scholar
• Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol. 2016;68(2):312–322.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ziouzina O, Thavaneswaran A, et al. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40(8):1357–1359.
   PubMed Web of Science ®Google Scholar
• van Kuijk AWR, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep. 2011;13(4):353–359.
   PubMed Web of Science ®Google Scholar
• Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76(6):675–705.
   PubMed Web of Science ®Google Scholar
• Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128.
   PubMed Web of Science ®Google Scholar
• Maejima H, Taniguchi T, Watarai A, et al. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol. 2010;49(8):901–906.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17(6):809–812.
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatol Oxf Engl. 2003;42(6):778–783.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118–126.
   PubMed Web of Science ®Google Scholar
• Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020;39(1):217–225.
   PubMed Web of Science ®Google Scholar
• Merola JF, Shrom D, Eaton J, et al. Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey. Rheumatol Ther. 2019;6(1):33–45.
   PubMed Web of Science ®Google Scholar
• Frischknecht L, Vecellio M, Selmi C. The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19886505.
   PubMed Web of Science ®Google Scholar
• Pollock RA, Abji F, Gladman DD. Epigenetics of psoriatic disease: a systematic review and critical appraisal. J Autoimmun. 2017;78:29–38.
   PubMed Web of Science ®Google Scholar
• Richmond JM, Harris JE. Immunology and skin in health and disease. Cold Spring Harb Perspect Med. 2014;4(12):a015339.
   PubMed Web of Science ®Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645–653.
   PubMed Web of Science ®Google Scholar
• Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. The Lancet. 2018;391(10136):2273–2284.
   PubMed Web of Science ®Google Scholar
• Liang Y, Sarkar MK, Tsoi LC, et al. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8.
   PubMed Web of Science ®Google Scholar
• Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–851.
   PubMed Web of Science ®Google Scholar
• Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143(6):1177–1182.
   PubMed Web of Science ®Google Scholar
• Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526.
   PubMed Web of Science ®Google Scholar
• Rahmati S, Tsoi L, O'Rielly D, et al. Complexities in genetics of psoriatic arthritis. Curr Rheumatol Rep. 2020;22(4):10.
   PubMed Web of Science ®Google Scholar
• Zeng J, Luo S, Huang Y, et al. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863–872.
   PubMed Web of Science ®Google Scholar
• Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res. 2011;63(8):1091–1097.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135–143.
   PubMed Web of Science ®Google Scholar
• Gregorio J, Meller S, Conrad C, et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med. 2010;207(13):2921–2930.
   PubMed Web of Science ®Google Scholar
• Santini SM, Lapenta C, Donati S, et al. Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. Plos One. 2011;6(2):e17364.
   PubMed Web of Science ®Google Scholar
• De Smedt T, Pajak B, Muraille E, et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med. 1996;184(4):1413–1424.
   PubMed Web of Science ®Google Scholar
• Malakou LS, Gargalionis AN, Piperi C, et al. Molecular mechanisms of mechanotransduction in psoriasis. Ann Transl Med. 2018;6(12):245.
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007;33(1–2):45–56.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest. 1994;94(1):202–209.
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950–957.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556–567.
   PubMed Web of Science ®Google Scholar
• Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153–166.
   PubMed Web of Science ®Google Scholar
• Zabotti A, McGonagle DG, Giovannini I, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. 2019;5(2):e001067.
   PubMed Web of Science ®Google Scholar
• Zabotti A, Tinazzi I, Aydin SZ, et al. From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention. Curr Rheumatol Rep. 2020;22(6):24.
   PubMed Web of Science ®Google Scholar
• Talotta R, Atzeni F, Sarzi-Puttini P, et al. Psoriatic arthritis: from pathogenesis to pharmacologic management. Pharmacol Res. 2019;148:104394.
   PubMed Web of Science ®Google Scholar
• Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64(suppl):ii74–74.
   PubMedGoogle Scholar
• Lindqvist T, Salah L, Gillstedt M, et al. Methotrexate management in psoriasis: are we following the guidelines? Acta Derm Venereol. 2018;98(4):449–451.
   PubMed Web of Science ®Google Scholar
• Asiri A, Thavaneswaran A, Kalman-Lamb G, et al. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol. 2014;32(5):728–731.
   PubMed Web of Science ®Google Scholar
• Brownstone N, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician. Biol Targets Ther. 2021;15:39–51.
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Tramontano G, Gilio M, et al. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol Res Rev. 2017;9:21–28.
   PubMed Web of Science ®Google Scholar
• Kerschbaumer A, Smolen JS, Dougados M, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2020;79(6):778–786.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279–286.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.
   PubMed Web of Science ®Google Scholar
• Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res. 2015;76(5):215–227.
   PubMed Web of Science ®Google Scholar
• Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16(9):443.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Caposiena D, Garofalo V, et al. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Rev Clin Immunol. 2016;12(3):237–249.
   PubMed Web of Science ®Google Scholar
• Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015;95(2):133–139.
   PubMed Web of Science ®Google Scholar
• Schett G, Sloan VS, Stevens RM, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2(5):271–278.
   PubMedGoogle Scholar
• Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511.
   PubMed Web of Science ®Google Scholar
• Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370(Pt 1):1–18.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529–1538.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888–897.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029.
   PubMed Web of Science ®Google Scholar
• Afra TP, Razmi TM, Dogra S. Apremilast in psoriasis and beyond: big hopes on a small molecule. Indian Dermatol Online J. 2019;10(1):1–12.
   PubMedGoogle Scholar
• Lee EB, Amin M, Wu JJ. Drug survival of apremilast in patients treated for psoriasis in a real-world setting. J Am Acad Dermatol. 2018;79(4):760–761.
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–730.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet Lond Engl. 2013;381(9865):451–460.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, ORAL Scan Investigators, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–570.
   PubMed Web of Science ®Google Scholar
• Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–261.
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):510–515.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550.
   PubMed Web of Science ®Google Scholar
• Yan Z, Gibson SA, Buckley JA, et al. Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin Immunol Orlando Fla. 2018;189:4–13.
   PubMed Web of Science ®Google Scholar
• Benveniste EN, Liu Y, McFarland BC, et al. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res. 2014;34(8):577–588.
   PubMed Web of Science ®Google Scholar
• Gao W, McGarry T, Orr C, et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis. 2016;75(1):311–315.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American college of rheumatology. Arthritis Rheum. 1995;38(6):727–735.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536.
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2(1):23.
   PubMedGoogle Scholar
• Mohamed MEF, Beck D, Camp HS, et al. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-Response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol. 2020;60(2):188–197.
   PubMed Web of Science ®Google Scholar
• Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology. 2021;61(8):3257–3268.
   Web of Science ®Google Scholar
• Akpabio A, Adebajo A. Evaluating upadacitinib for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2022;23(2):169–173.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Winthrop K, Blanco R, et al. Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials. Rheumatol Ther. 2022;9(2):521–539.
   PubMed Web of Science ®Google Scholar
• Kragstrup TW, Glintborg B, Svensson AL, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1):e002236.
   PubMed Web of Science ®Google Scholar
• Torres T, Barcelos A, Filipe P, et al. A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. Front Med. 2021;7:618163.
   Web of Science ®Google Scholar
• West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLoS ONE. 2016;11(5):e0153740.
   PubMedGoogle Scholar
• Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–513.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Jarvis S, Boehncke WH, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the clear about psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200–2207.
   PubMed Web of Science ®Google Scholar
• Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48–53.
   PubMed Web of Science ®Google Scholar
• Rahman P, Zummer M, Bessette L, et al. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open. 2017;7(8):e016619.
   PubMed Web of Science ®Google Scholar
• Zardin-Moraes M, Azeredo-da-Silva ALF, Saldanha C, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-life studies and randomized clinical trials: systematic review with metanalysis. J Rheumatol. 2019;47(6):839–846.
   PubMed Web of Science ®Google Scholar
• Coates LC, Mease PJ, Gossec L, et al. Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res. 2018;70(10):1529–1535.
   Web of Science ®Google Scholar
• Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol. 2018;45(1):6–13.
   PubMed Web of Science ®Google Scholar
• Queiro R, Cañete JD, Montilla C, et al. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther. 2017;19(1):72.
   PubMedGoogle Scholar
• Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91–102.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382–390.
   PubMed Web of Science ®Google Scholar
• Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000;273(2):793–798.
   PubMed Web of Science ®Google Scholar
• Gregoretti I, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338(1):17–31.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9(3):206–218.
   PubMed Web of Science ®Google Scholar
• Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.
   PubMed Web of Science ®Google Scholar
• Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A. 1999;96(9):4868–4873.
   PubMed Web of Science ®Google Scholar
• Johnson CA, White DA, Lavender JS, et al. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J Biol Chem. 2002;277(11):9590–9597.
   PubMed Web of Science ®Google Scholar
• Hu E, Chen Z, Fredrickson T, et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem. 2000;275(20):15254–15264.
   PubMed Web of Science ®Google Scholar
• Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 2013;280(3):775–793.
   PubMed Web of Science ®Google Scholar
• Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A. 2007;104(44):17335–17340.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–840.
   PubMed Web of Science ®Google Scholar
• Kim E, Bisson WH, Löhr CV, et al. Histone and non-histone targets of dietary deacetylase inhibitors. Curr Top Med Chem. 2016;16(7):714–731.
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, et al. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15–23.
   PubMed Web of Science ®Google Scholar
• Marmorstein R, Zhou MM. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb Perspect Biol. 2014;6(7):a018762.
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol. 2011;31(3):233–263.
   PubMed Web of Science ®Google Scholar
• Hong L, Schroth GP, Matthews HR, et al. Studies of the DNA binding properties of histone H4 amino terminus thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 “tail” to DNA. J Biol Chem. 1993;268(1):305–314.
   PubMed Web of Science ®Google Scholar
• Das C, Kundu T. Transcriptional regulation by the acetylation of nonhistone proteins in humans - a new target for therapeutics. IUBMB Life. 2005;57(3):137–149.
   PubMed Web of Science ®Google Scholar
• Fischle W, Verdin E, Greene WC, et al. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001;293(5535):1653–1657.
   PubMed Web of Science ®Google Scholar
• Koeneke E, Witt O, Oehme I. HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities. Cells. 2015;4(2):135–168.
   PubMed Web of Science ®Google Scholar
• Valenzuela-Fernández A, Cabrero JR, Serrador JM, et al. HDAC6: a key regulator of cytoskeleton, cell migration and cell–cell interactions. Trends Cell Biol. 2008;18(6):291–297.
   PubMed Web of Science ®Google Scholar
• Telles E, Seto E. Modulation of cell cycle regulators by HDACs. Front Biosci Sch Ed. 2012;4:831–839.
   Google Scholar
• Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol. 2019;20(3):156–174.
   PubMed Web of Science ®Google Scholar
• Hu Y, Suliman BA. Roles of HDACs in the responses of innate immune cells and as targets in inflammatory diseases. In: Xu D, editor. Regulation of inflammatory signaling in health and disease. Advances in experimental medicine and biology. Singapore: Springer; 2017. p. 91–110.
   Google Scholar
• Shakespear MR, Halili MA, Irvine KM, et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011;32(7):335–343.
   PubMed Web of Science ®Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19–25.
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391–400.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by bcl-2/Bcl-X L, c-Jun, and p21 CIP1, but independent of p53. Oncogene. 1999;18(50):7016–7025.
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000;97(18):10014–10019.
   PubMed Web of Science ®Google Scholar
• Sandor V, Senderowicz A, Mertins S, et al. P21-dependent G 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000;83(6):817–825.
   PubMed Web of Science ®Google Scholar
• Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell. 2004;6(4):361–371.
   PubMed Web of Science ®Google Scholar
• Eckschlager T, Plch J, Stiborova M, et al. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):1414.
   PubMed Web of Science ®Google Scholar
• Zupkovitz G, Tischler J, Posch M, et al. Negative and positive regulation of gene expression by mouse histone Deacetylase1. Mol Cell Biol. 2006;26(21):7913–7928.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007;21(14):1790–1802.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Potthoff MJ, Haberland M, et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest. 2008;118(11):3588–3597.
   PubMed Web of Science ®Google Scholar
• Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002;111(5):709–720.
   PubMed Web of Science ®Google Scholar
• Yuan PX, Huang LD, Jiang YM, et al. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem. 2001;276(34):31674–31683.
   PubMed Web of Science ®Google Scholar
• Asghari V, Wang JF, Reiach JS, et al. Differential effects of mood stabilizers on fos/jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res. 1998;58(1–2):95–102.
   PubMedGoogle Scholar
• Mani S, Shen Y, Schaefer J, et al. Failure to express GAP-43 during neurogenesis affects cell cycle regulation and differentiation of neural precursors and stimulates apoptosis of neurons. Mol Cell Neurosci. 2001;17(1):54–66.
   PubMed Web of Science ®Google Scholar
• Chen S, Yao X, Li Y, et al. Histone deacetylase 1 and 2 regulate wnt and p53 pathways in the ureteric bud epithelium. Dev Camb Engl. 2015;142(6):1180–1192.
   PubMed Web of Science ®Google Scholar
• Shieh JM, Tang YA, Hu FH, et al. A histone deacetylase inhibitor enhances expression of genes inhibiting wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer. Int J Cancer. 2017;140(10):2375–2386.
   PubMed Web of Science ®Google Scholar
• Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol. 2005;70(3):394–406.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Bates SE, Wright JJ, et al. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals. 2010;3(9):2751–2767.
   Google Scholar
• Shah RR. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 2019;42(2):235–245.
   PubMed Web of Science ®Google Scholar
• Chang P, Weykamp M, Dennahy IS, et al. Histone deacetylase inhibitors: isoform selectivity improves survival in a hemorrhagic shock model. J Trauma Acute Care Surg. 2018;84(5):795–801.
   PubMed Web of Science ®Google Scholar
• Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today. 2015;20(6):718–735.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han Y, Jiang Q, et al. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med Res Rev. 2015;35(1):63–84.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med. 2011;17(5–6):333–352.
   PubMed Web of Science ®Google Scholar
• Shuttleworth SJ, Bailey SG, Townsend PA. Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010;11(11):1430–1438.
   PubMed Web of Science ®Google Scholar
• McLaughlin F, La Thangue NB. Histone deacetylase inhibitors in psoriasis therapy. Curr Drug Targets Inflamm Allergy. 2004;3(2):213–219.
   PubMedGoogle Scholar
• Adcock IM. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol. 2007;150(7):829–831.
   PubMed Web of Science ®Google Scholar
• Tovar-Castillo LE, Cancino-Díaz JC, García-Vázquez F, et al. HIF-1α, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol. 2006;46(3):239–246.
   Web of Science ®Google Scholar
• Hwang YJ, Na JI, Byun SY, et al. Histone deacetylase 1 and sirtuin 1 expression in psoriatic skin: a comparison between guttate and plaque psoriasis. Life. 2020;10(9):157.
   PubMedGoogle Scholar
• Zhang P, Su Y, Zhao M, et al. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur J Dermatol. 2011;21(4):552–557.
   PubMed Web of Science ®Google Scholar
• Ovejero‐Benito MC, Reolid A, Sánchez‐Jiménez P, et al. Histone modifications associated with biological drug response in moderate‐to‐severe psoriasis. Exp Dermatol. 2018;27(12):1361–1371.
   PubMed Web of Science ®Google Scholar
• Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A. 2002;99(5):2995–3000.
   PubMed Web of Science ®Google Scholar
• Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of Pro-Inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005;11(1–12):1–15.
   PubMed Web of Science ®Google Scholar
• Li S, Fossati G, Marchetti C, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015;290(4):2368–2378.
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Krausz S, de Jager W, et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol. 2010;184(5):2718–2728.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Beck J, Werth D, et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res. 2007;13(13):3933–3941.
   PubMed Web of Science ®Google Scholar
• Wang B, Morinobu A, Horiuchi M, et al. Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. Cell Immunol. 2008;253(1–2):54–58.
   PubMed Web of Science ®Google Scholar
• Bosisio D, Vulcano M, Del Prete A, et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol. 2008;84(6):1540–1548.
   PubMed Web of Science ®Google Scholar
• Salvi V, Bosisio D, Mitola S, et al. Trichostatin a blocks type I interferon production by activated plasmacytoid dendritic cells. Immunobiology. 2010;215(9–10):756–761.
   PubMed Web of Science ®Google Scholar
• Brogdon JL, Xu Y, Szabo SJ, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2007;109(3):1123–1130.
   PubMed Web of Science ®Google Scholar
• Skov S, Rieneck K, Bovin LF, et al. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood. 2003;101(4):1430–1438.
   PubMed Web of Science ®Google Scholar
• Schotterl S, Brennenstuhl H, Naumann U. Modulation of immune responses by histone deacetylase inhibitors. Crit Rev Oncog. 2015;20(1–2):139–154.
   PubMedGoogle Scholar
• Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13(11):1299–1307.
   PubMed Web of Science ®Google Scholar
• Koenen HJPM, Smeets RL, Vink PM, et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17–producing cells. Blood. 2008;112(6):2340–2352.
   PubMed Web of Science ®Google Scholar
• Samanta A, Li B, Song X, et al. TGF- and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci U S A. 2008;105(37):14023–14027.
   PubMed Web of Science ®Google Scholar
• Lucas JL, Mirshahpanah P, Haas-Stapleton E, et al. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol. 2009;257(1–2):97–104.
   PubMed Web of Science ®Google Scholar
• Akimova T, Ge G, Golovina T, et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ tregs. Clin Immunol Orlando Fla. 2010;136(3):348–363.
   PubMed Web of Science ®Google Scholar
• Nishida K, Komiyama T, Miyazawa S, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21WAF1/Cip1 expression. Arthritis Rheum. 2004;50(10):3365–3376.
   PubMed Web of Science ®Google Scholar
• Morinobu A, Wang B, Liu J, et al. Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts. J Rheumatol. 33(6):1052–1060.
   PubMed Web of Science ®Google Scholar
• Jüngel A, Baresova V, Ospelt C, et al. Trichostatin a sensitises rheumatoid arthritis synovial fibroblasts for TRAIL‐induced apoptosis. Ann Rheum Dis. 2006;65(7):910–912.
   PubMed Web of Science ®Google Scholar
• Manabe H, Nasu Y, Komiyama T, et al. Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflamm Res off J Eur Histamine Res Soc Al. 2008;57(1):4–10.
   Google Scholar
• Choo QY, Ho PC, Tanaka Y, et al. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatol Oxf Engl. 2010;49(8):1447–1460.
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Korchynskyi O, Tak PP, et al. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis. 2012;71(3):424–431.
   PubMed Web of Science ®Google Scholar
• Angiolilli C, Kabala PA, Grabiec AM, et al. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Ann Rheum Dis. 2017;76(1):277–285.
   PubMed Web of Science ®Google Scholar
• Bruhs A, Schwarz T, Schwarz A. 325 The short chain fatty acid sodium butyrate attenuates imiquimod-induced psoriasis-like skin inflammation. J Invest Dermatol. 2017;137(10):S248.
   PubMed Web of Science ®Google Scholar
• Khmaladze I, Kelkka T, Guerard S, et al. Mannan induces ROS-regulated, IL-17A–dependent psoriasis arthritis-like disease in mice. Proc Natl Acad Sci U S A. 2014;111(35):E3669–E3678.
   PubMed Web of Science ®Google Scholar
• Cantley MD, Fairlie DP, Bartold PM, et al. Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis. Rheumatology. 2015;54(9):1713–1723.
   PubMed Web of Science ®Google Scholar
• Sellmer A, Stangl H, Beyer M, et al. Marbostat-100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors. J Med Chem. 2018;61(8):3454–3477.
   PubMed Web of Science ®Google Scholar
• Park JK, Jang YJ, Oh BR, et al. Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):176.
   PubMed Web of Science ®Google Scholar
• Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs. 2014;25(2):140–149.
   PubMed Web of Science ®Google Scholar
• Vojinovic J, Damjanov N, D'Urzo C, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(5):1452–1458.
   PubMedGoogle Scholar
• Italfarmaco P. II, Open label, international, multicentre clinical trial to investigate safety and efficacy of oral ITF2357 in patients with active systemic onset juvenile idiopathic arthritis (SOJIA) [Internet]. clinicaltrials.gov; 2021. [cited 2021 Jun 3]. Report No.: NCT00570661. Available from: https://clinicaltrials.gov/ct2/show/NCT00570661.
   Google Scholar
• Barut K, Adrovic A, Şahin S, et al. Juvenile idiopathic arthritis. Balkan Med J. 2017;34(2):90–101.
   PubMed Web of Science ®Google Scholar
• Juvenile Idiopathic Arthritis (JIA) | Arthritis Foundation [Internet]. [cited 2021 Jun 7]. Available from: https://www.arthritis.org/diseases/juvenile-idiopathic-arthritis.
   Google Scholar
• Moosavi A, Ardekani AM. Role of epigenetics in biology and human diseases. Iran Biomed J. 2016;20(5):246–258.
   PubMedGoogle Scholar
• Ekman AK, Enerbäck C. Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis. Br J Dermatol. 2016;174(2):424–426.
   PubMed Web of Science ®Google Scholar
• Parra M, Verdin E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr Opin Pharmacol. 2010;10(4):454–460.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023–17023.
   PubMed Web of Science ®Google Scholar
• Kiernan R, Brès V, Ng RWM, et al. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem. 2003;278(4):2758–2766.
   PubMed Web of Science ®Google Scholar
• Furumai R, Ito A, Ogawa K, et al. Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci. 2011;102(5):1081–1087.
   PubMed Web of Science ®Google Scholar